Catalogue Number: 11106-IBL
|Manufacturer:||IBL - (Immuno-Biologicals Laboratories Co Ltd)|
|Physical state:||Lyophilized product from 1 % BSA in PBS containing 0.05 % NaN3|
|Type:||Monoclonal Primary Antibody - Unconjugated|
|Shipping Condition:||Blue Ice|
|Unit(s):||100 ug, 10 ug|
|Immunogen:||Recombinant human YB-1|
Description: YB-1 (Y-box binding protein-1) contains a highly conserved cold shock domain and is a transcription factor that binds to a CCAAT box. It has been reported that P-glycoprotein is highly expressed in cisplatin-resistant cancer cell lines since the sequence of CCAAT box is located in the promoter region of the drug-resistance gene MDR1, and YB-1 is involved in transcription of P-glycoprotein, the product of the MDR1 gene. YB-1 is usually present in the cytoplasm, but it translocates into the nucleus in cancer cells that have been exposed to UV radiation or anticancer drugs. And it is thought to be involved in DNA damage or repair in association with PCNA or p53. YB-1 is also highly expressed in the nucleus in about half of non-small cell lung cancers, and the outcome has been reported to be particularly poor in cases of squamous cell carcinoma in which it is expressed in the nucleus. It has also been reported that, with a 5-year recurrence rate of 66%, the outcome of YB-1-positive cases is poor in breast cancer cases treated with postoperative chemotherapy (in YB-1-negative cases the rate is 0%), and that there is no correlation with HER2 expression. Recently, YB-1 has been reported to be a prognostic marker of hepatocellular carcinoma.